Pyrazoloacridine

Preferred Label : Pyrazoloacridine;

NCIt definition : A 9-methoxy acridine compound containing a reducible 5-nitro substituent. Pyrazoloacridine appears to intercalate into DNA and inhibit RNA synthesis, DNA synthesis, and the activities of topoisomerases I and II, thereby causing cytotoxicity. (NCI04);

Alternative definition : NCI-GLOSS: A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called acridines.;

UNII : L24XJN68OW;

CAS number : 99009-20-8;

NSC code : 366140;

Codes from synonyms : CDR0000045366;

Details

Origin ID

C1564;

UMLS CUI

C0280970;

Automatic exact mappings (from CISMeF team)
- NSC 366140 [MeSH Supplementary Concept]
Currated CISMeF NLP mapping
- 9-methoxy-N,N-dimethyl-5-nitropyrazolo(3,4,5-k)acridine-2(6H)-propanamine [MeSH concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- 9-methoxy-N,N-dimethyl-5-nitropyrazolo(3,4,5-k)acridine-2(6H)-propanamine [MeSH concept]
chemical_or_drug_has_mechanism_of_action
- DNA Intercalation [NCIt concept]
chemical_or_drug_has_physiologic_effect
- DNA Replication Inhibition [NCIt concept]
- RNA Synthesis Inhibition [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- DNA [NCIt concept]
- DNA Topoisomerase 1 [NCIt concept]
- Topoisomerase II [NCIt concept]
is_component_of_chemotherapy_regimen
- Carboplatin/Pyrazoloacridine [NCIt concept]
- Cisplatin/Filgrastim/Pyrazoloacridine [NCIt concept]
- Cisplatin/Pyrazoloacridine [NCIt concept]
- Filgrastim/Pyrazoloacridine [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients